Drug intelligence / Profile preview

Lanzha Glycoside Capsule

Development stage: Unknown
Lead developer: Sichuan Pearl Pharmaceutical
Administration: Oral

Overview

**Lanzha Glycoside Capsule** is an oral traditional Chinese medicine or natural-product capsule developed by Sichuan Pearl Pharmaceutical for treatment of dyslipidemia, including hyperlipidemia. It was evaluated in China in a multicenter, randomized, double-blind, placebo-controlled Phase 2 study, CTR20130234, which examined efficacy and safety at different dose levels. Publicly available registry-derived records do not identify its precise botanical composition, individual active constituent structure, or molecular target; therefore, a specific pharmacologic mechanism cannot be assigned. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/60dd53a443db4d188ed1f8fe9d8ced18))

Other names: Lanzha Tonggan蓝楂酮苷胶囊

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on Lanzha Glycoside Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lanzha Glycoside Capsule.

Explore the full profile